#Stada

@newsen.bsky.social

1 month ago

STADA and Bio-Thera Launch Gotenfia®, a New Biosimilar to Simponi in Europe STADA and Bio-Thera have gained European authorization for Gotenfia®, a biosimilar of Simponi. This innovative treatment targets autoimmune diseases and enhances patient access across Europe.

STADA and Bio-Thera Launch Gotenfia®, a New Biosimilar to Simponi in Europe #Germany #Bio-Thera #STADA #Gotenfia #Bad_Vilbel

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 months ago

STADA and Bio-Thera Celebrate EMA's Positive Opinion for Gotenfia, a Golimumab Biosimilar STADA and Bio-Thera's golimumab biosimilar, Gotenfia, has received a positive opinion from the EMA, paving the way for its approval in the EU and several other countries.

STADA and Bio-Thera Celebrate EMA's Positive Opinion for Gotenfia, a Golimumab Biosimilar #Germany #Bio-Thera #STADA #Gotenfia #Bad_Vilbel

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

6 months ago

Canson Capital Partners Leads CapVest's Acquisition of STADA Canson Capital Partners has announced its role as the lead financial advisor for CapVest Partners in its acquisition of STADA, marking a significant milestone in its investment journey.

Canson Capital Partners Leads CapVest's Acquisition of STADA #London #United_Kingdom #STADA #Canson_Capital #CapVest

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

6 months ago

Canson Capital Partners Leads Financial Advisory Role in CapVest's Acquisition of STADA Canson Capital Partners has successfully acted as the lead financial advisor for CapVest's acquisition of STADA, marking a significant milestone in private equity transactions.

Canson Capital Partners Leads Financial Advisory Role in CapVest's Acquisition of STADA #London #United_Kingdom #STADA #Canson_Capital #CapVest

0 0 0 0

pharmaphorum

@pharmaphorum.bsky.social

6 months ago

IPO plan evaporates as private equity firm buys Stada Stada has confirmed it isn't going ahead with an IPO, as its two private equity owners have just agreed to sell a majority stake to a third.

Reports last week that German pharma group #Stada was planning an initial public offering (IPO) were erroneous, as the company has just agreed to a change in #privateownership.

pharmaphorum.com/news/ipo-pla...

0 0 0 0

40:40 Recruitment - celia@4040recruitment.co.uk

@4040rec.bsky.social

6 months ago

Stada revives talk of an IPO – if conditions improve Germany's Stada has said it may make another attempt to seek a public listing in the autumn, after delaying its plans earlier this year.

#Stada #IPO #pharmaindustry #generics #OTC #specialtymedicines #rarediseases #chronicdiseases #biosimilars #plaquepsoriasis #psoriaticarthritis #Crohnsdisease #specialtybiosimilars #aflibercept #denosumab #golimumab #tocilizumab #blockbusterdrugs #GLP1agonists #diabetes #obesity
zurl.co/nbsw4

0 0 0 0

Profit Trading USA

@profittradingusa.bsky.social

6 months ago

CapVest strikes deal to buy majority of Stada from Bain, Cinven Investing.com -- Bain Capital and Cinven in a joint statement on Monday said they will sell a majority stake in German drugmaker Stada Arzneimittel AG to CapVest Partners LLP, with the deal expected to close in the first half of 2026 . Bain Capital and Cinven acquired Stada in 2017 and took it private. Under their ownership, the company expanded from a traditional generics business into a diversified healthcare platform with operations in consumer healthcare, generics and specialty pharmaceuticals. Stada reported sales of €4.06 billion in 2024 and adjusted EBITDA of €886 million, employing about 11,600 people worldwide. During the eight years of ownership, the firms supported more than 25 acquisitions, including Johnson & Johnson’s Nizoral brand, Czech supplement maker Walmark, and consumer health portfolios from GlaxoSmithKline and Sanofi. The acquisitions expanded Stada’s presence in Europe and other markets . Stada’s chief executive officer Peter Goldschmidt said the company grew internationally and increased innovation under Bain and Cinven. Dr. Michael Siefke, a partner at Bain Capital, said the firm worked to strengthen consumer healthcare, generics and specialty medicines during its investment. Supraj Rajagopalan, co-managing partner at Cinven, said the company invested in digitalization, operational improvements and governance structures. CapVest specializes in healthcare investments and will become the new majority owner. Bain Capital and Cinven will retain minority stakes in Stada after the transaction closes. Jefferies and Rothschild & Co are serving as lead merger-and-acquisition advisers. The terms of the transaction were not disclosed. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. Which stocks should you consider in your very next trade? The best opportunities often hide in plain sight—buried among thousands of stocks you'd never have time to research individually. That's why smart investors use our Stock Screener with 50+ predefined screens and 160+ customizable filters to surface hidden gems instantly. For example, the Piotroski's Picks method averages 23% annual returns by focusing on financial strength, and you can get it as a standalone screen. Momentum Masters catches stocks gaining serious traction, while Blue-Chip Bargains finds undervalued giants. With screens for dividends, growth, value, and more, you'll discover opportunities others miss. Our current favorite screen is Under $10/share, which is great for discovering stocks trading under $10 with recent price momentum showing some very impressive returns!

Click Subscribe #CapVest #Stada #BainCapital #Cinven #PrivateEquity

0 0 0 0

J.H. Rupprecht

@rupprecht.bsky.social

6 months ago

Stada: Finanzinvestor CapVest vor Übernahme des Generikaherstellers Zuletzt stand ein Börsengang im Herbst im Raum. Nun heißt es, dass Londoner Finanzinvestor CapVest den Arzneihersteller Stada kaufen will. Der Kaufpreis soll 10 Milliarden Euro betragen.

NEU Arzneimittelhersteller #Stada: Stand zuletzt ein Börsengang im Herbst im Raum, heißt es nun, dass Londoner Finanzinvestor #CapVest das deutsche Pharmaunternehmen kaufen will. Der Kaufpreis soll 10 Mrd. Euro betragen #Generika #Medizin #Deutschland #Pharma #Industrie #Produktion #Pharmaindustrie

1 0 0 0

Profit Trading USA

@profittradingusa.bsky.social

6 months ago

CapVest nears €10 bln deal for German drugmaker Stada – Bloomberg Investing.com-- CapVest Partners is close to striking a deal to acquire Stada Arzneimittel AG for about €10 billion ($11.7 billion) including debt, Bloomberg reported on Sunday, citing people familiar with the matter. The London-based buyout firm is finalising terms with Stada’s private equity owners Bain Capital and Cinven, and an announcement could come as soon as Monday if talks do not falter, Bloomberg said. Previous negotiations stumbled over valuation and legal liabilities, prompting Bain and Cinven to consider an initial public offering before CapVest returned to the table, according to the report. A deal would mark one of the biggest private equity exits in Europe this year, at a time when firms are under pressure to sell long-held assets and return capital to investors. Stada, bought by Bain and Cinven for €5.3 billion in 2017, makes consumer health products, generic medicines, and specialty drugs. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. Which stock should you buy in your very next trade? AI computing powers are changing the stock market. Investing.com's ProPicks AI includes dozens of winning stock portfolios chosen by our advanced AI. Year to date, 3 out of 4 global portfolios are beating their benchmark indexes, with 98% in the green. Our flagship Tech Titans strategy doubled the S&P 500 within 18 months, including notable winners like Super Micro Computer (+185%) and AppLovin (+157%). Which stock will be the next to soar?

Click Subscribe #CapVest #Stada #Acquisition #PrivateEquity #Pharmaceuticals

0 0 0 0

Profit Trading USA

@profittradingusa.bsky.social

6 months ago

Stada aims for autumn IPO, reports 6% revenue growth in first half Investing.com -- German pharmaceutical company Stada is preparing for an initial public offering this fall, The Wall Street Journal reports, following a postponement earlier this year due to geopolitical uncertainty and market volatility. "We are preparing an IPO in the autumn, provided the general conditions are right," Stada Chief Executive Peter Goldschmidt said in an emailed statement to the Journal on Thursday. The private-equity backed company joins a small group of firms planning to list before year-end, after European IPO activity fell to its lowest level since early 2020 during the first half of 2025. Other companies planning listings include Thyssenkrupp’s naval division TKMS, which aims to debut on the Frankfurt Stock Exchange in mid-October, and Aumovio, a Continental AG spinoff expected to list next month. Deutsche Börse is also considering an IPO for its ISS Stoxx operations this year. Stada’s renewed IPO plans come as the company reported strong financial results for the first half of 2025. The group achieved 6% growth in adjusted constant-currency revenues, while adjusted constant-currency EBITDA improved by 5% to a record level. The company saw revenue growth across all three of its business segments: Consumer Healthcare, Generics, and Specialty. "Despite volatile market conditions, STADA achieved broad-based growth in the first half of this year, based on our diversified portfolio, strong launches and very high employee engagement rates," Goldschmidt said. The company also expanded its development portfolio with 50 new Business Development & Licensing deals signed in the first half of 2025. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. Goldschmidt expressed confidence in meeting full-year guidance, noting that Stada’s "exposure to the US market, and to tariff reforms, is very limited." Several companies, including StubHub and Klarna, delayed their IPOs earlier this year amid market volatility attributed to U.S. President Trump’s tariff policies. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Should you invest $2,000 in CONG right now? First, check if it's included in one of this month's AI-powered stock strategies for ProPicks AI. Investing.com created these strategies to identify the most exciting trading opportunities currently in the market. The stocks that made the cut could produce monster returns in the coming years, like ViaSat and Sapiens , both up over 60%+ each in Q2 of 2025 alone. Is CONG one of them?

Click Subscribe #Stada #IPO #AutumnIPO #RevenueGrowth #StockMarket

0 0 0 0

pharmaphorum

@pharmaphorum.bsky.social

6 months ago

German #pharma company #Stada has said it may make another attempt to seek a #publiclisting in the autumn, after delaying its plans earlier this year.

buff.ly/TNhDbOh

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

6 months ago

Bio-Thera and STADA Strengthen Biosimilar Partnership for Tocilizumab Immunotherapy Bio-Thera and STADA extend their collaboration in biosimilars with tocilizumab targeting inflammatory disorders. This alliance enhances patient access to treatment.

Bio-Thera and STADA Strengthen Biosimilar Partnership for Tocilizumab Immunotherapy #China #Guangzhou #Bio-Thera #STADA #Tocilizumab

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

6 months ago

Bio-Thera and STADA Expand Strategic Partnership to Include Tocilizumab Biosimilars Bio-Thera and STADA have agreed to expand their biosimilars alliance to include tocilizumab, enhancing treatment options for various autoimmune conditions.

Bio-Thera and STADA Expand Strategic Partnership to Include Tocilizumab Biosimilars #China #Guangzhou #Bio-Thera #Biosimilars #STADA

0 0 0 0

Profit Trading USA

@profittradingusa.bsky.social

8 months ago

Stada resumes investor meetings for September IPO - Bloomberg Investing.com -- German drugmaker Stada Arzneimittel AG has resumed meeting with investors this month for its initial public offering, which could take place as early as September, according to Bloomberg, citing people familiar with the matter. Private equity owners Bain Capital and Cinven are seeking a valuation of approximately €10 billion ($11.7 billion) for the company, though this figure could change based on investor feedback, the sources said, asking not to be identified as the information is private. Stada had previously delayed its planned IPO to September due to market volatility in March. The company is targeting to raise around €1.5 billion in fresh capital from the offering, in addition to any potential selldown from its owners. The sources indicated that deliberations are still ongoing and no final decisions have been made regarding the listing. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Which stock should you buy in your very next trade? With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Unsure where to invest next? Get access to our proven portfolios and discover high-potential opportunities. In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech stocks, and Mid Cap stocks, you can explore various wealth-building strategies.

Click Subscribe #Stada #IPO #InvestorMeetings #StockMarket #FinanceNews

0 0 0 0

Dirk Bürger

@buerger-berlin.bsky.social

1 year ago

Stada erwägt Börsengang im April

"2023 steigerte #STADA seinen Umsatz um 14% auf 3,7 Mrd. €. Der #Gewinn vor Zinsen, Steuern & Abschreibungen erhöhte sich um 19% auf 802 Mio. €." aus @tspbackground.bsky.social "Stada erwägt #Börsengang 📈 im April": background.tagesspiegel.de/gesundheit-u... #Pharma

0 0 0 0

Werner Keil

@wernerkeil.bsky.social

1 year ago

Bekannte Pharmafirma hat ihren Sitz in der Wetterau – nun folgt milliardenschwerer Börsengang Ein hessischer Arzneihersteller plant einen Börsengang. Ein erfahrener Ex-Bayer-Manager übernimmt hierbei eine wichtige Rolle.

Ein #hessischer #Arzneihersteller #Stada plant erneut einen #Börsengang. Ein erfahrener Ex-#Bayer-Manager übernimmt hierbei eine wichtige Rolle. www.fnp.de/lokales/wett...

0 0 0 0

Nebenwerte Magazin

@nebenwerte-magazin.bsky.social

1 year ago

#Stada #Reifenkartell Maut #LKWKartell im Blick. Fachanwalt rät! Geht was. Nicht nur bei Stada, sondern auch beim Reifenkartell, der #Maut und... Aktien #börse #Schadensersatz #Anwalt #wirecard
www.nebenwerte-magazin.com/?p=34632

0 0 0 0

Posts tagged #Stada